1. Home
  2. ANTX
  3. Earnings

AI Earnings Predictions for AN2 Therapeutics Inc. (ANTX)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-2.85%

$3.90

0% positive prob.

5-Day Prediction

-9.38%

$3.63

0% positive prob.

20-Day Prediction

-19.29%

$3.24

0% positive prob.

Price at prediction: $4.01 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -2.85% -9.38% -19.29% 100.0% Pending
Q2 2026 BUY +12.30% +37.47% +35.39% 100.0% Pending
Q1 2026 SELL -2.02% -9.92% -19.56% 100.0% -5.08%
Q4 2025 SELL -1.22% -7.77% -17.38% 100.0% Pending
Q3 2025 SELL -0.72% -7.65% -20.41% 100.0% -8.47%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-2.85%

$3.90

Act: +7.75%

5D

-9.38%

$3.63

20D

-19.29%

$3.24

Price: $4.01 Prob +5D: 0% AUC: 1.000
0001193125-26-452660

EX-99.1

2 antx-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end

Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease

Advancing startup activities for Phase 2 study of AN2-502998 in chronic Chagas disease

AN2-504661 selected as oral development candidate for hypophosphatasia (HPP)

Extended third-party funding supports AN2's tuberculosis research activities under its collaboration with GSK

Menlo Park, CA – November 9, 2026 – AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights.

“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform,” said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. “With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities. We also recently presented the Phase 2 study design at the MPN Congress, while continuing to advance our programs in M. abscessus and Chagas disease. Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas. With multiple clinical and development milestones ahead, we believe we are well positioned to continue building value across a diverse pipeline of differentiated boron-based therapies.”

Third Quarter & Recent Business Updates:

Polycythemia vera (PV)

• Phase 2 global study of oral epetraborole in PV cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end

Startup activities are underway for a global Phase 2 study to evaluate the efficacy and safety of oral epetraborole in adults with phlebotomy-dependent PV. The Company has received regulatory clearance to proceed in all planned jurisdictions, including U.S. FDA clearance of its IND, and regulatory clearances in Australia and India. The Company anticipates commencing enrollment by the end of 2026, beginning with an open-label sentinel cohort receiving a

predicted subtherapeutic dose to assess pharmacokinetics and safety in PV patients. Following completion of the sentinel group, the safety monitoring committee will advise on dose selection for Part 1, an open-label, single-arm, dose escalation, 28-week evaluation of epetraborole to maintain hematocrit control and reduce the frequency of phlebotomy in patients with phlebotomy-dependent PV. The Company anticipates releasing Part 1 data periodically throughout 2027.

In August 2026, the Company presented four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole in PV at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. In October 2026, the Company presented a poster at the18th International Congress on Myeloproliferative Neoplasms detailing the design of its Phase 2 clinical trial evaluating epetraborole in patients with PV.

M. abscessus complex lung disease

• Enrollment ongoing in Phase 2 investigator-initiated clinical trial of epetraborole in patients with M. abscessus lung disease

Building on the microbiological and safety data from the Company’s prior non-tuberculous mycobacterial (NTM) study in treatment-refractory Mycobacterium avium complex (MAC), the Company believes that epetraborole has the potential to address a critical unmet need in M. abscessus lung disease, one of the most difficult-to-treat NTM infections for which no FDA-approved therapy exists. The Company is supporting an investigator-initiated trial of oral epetraborole in M. abscessus and anticipates that data from this study, if positive, could provide clinical proof-of-concept in M. abscessus lung disease and thereby inform the design of a subsequent pivotal trial. Patient enrollment is ongoing. The 84-patient, multicenter, randomized, double-blind, placebo-controlled, prospective clinical study is being led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at the Oregon Health and Science University, in conjunction with other investigators across an estimated 10 to 15 sites in the U.S. The Company anticipates reporting topline results in late 2027, subject

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 11, 2026 · 100% conf.

AI Prediction BUY

1D

+12.30%

$6.59

Act: +6.98%

5D

+37.47%

$8.07

20D

+35.39%

$7.95

Price: $5.87 Prob +5D: 100% AUC: 1.000
0001193125-26-344549

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K SELL

May 11, 2026 · 100% conf.

AI Prediction SELL

1D

-2.02%

$4.62

Act: -9.53%

5D

-9.92%

$4.25

Act: -5.08%

20D

-19.56%

$3.80

Act: -17.16%

Price: $4.72 Prob +5D: 0% AUC: 1.000
0001193125-26-216752

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333650.ccaa516b

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About AN2 Therapeutics Inc. (ANTX) Earnings

This page provides AN2 Therapeutics Inc. (ANTX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ANTX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: